IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine which participants with melanoma have a better
response to IL-2 and to identify markers that may predict response to IL-2 by collecting
participant information (for example; cancer diagnosis and history, prior treatments for
cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after
treatment.